Dr. Mahesh Seetharam
Claim this profileMayo Clinic
Studies Tumors
Studies Cancer
17 reported clinical trials
29 drugs studied
About Mahesh Seetharam
Education:
- Obtained MBBS from Mysore Medical College, India, in 1997.
- Completed residency at Albert Einstein College of Medicine Jacobi Medical Center, becoming Chief Resident in 2007.
- Fellowship in Hematology/Oncology at Stanford University Hospital in 2010.
Experience:
- Board-certified in Medical Oncology and Hematology by the American Board of Internal Medicine since 2010.
- Served in leadership roles within The Arizona Clinical Oncology Society (TACOS), including President from 2017 to 2019.
- Active member of several professional societies, including the American Society of Clinical Oncology and American Society of Hematology.
Area of expertise
1Tumors
Stage IV
BRAF positive
BRAF
2Cancer
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Mahesh Seetharam is currently running
CDK4/6 Inhibitor
for Liposarcoma
This trial tests SPH4336, a chemotherapy pill, in patients with CDK4-positive liposarcomas. The drug works by blocking an enzyme that cancer cells need to grow, aiming to stop tumor growth.
Recruiting1 award Phase 2
E6201 + Dabrafenib
for Brain Metastasis from Melanoma
This phase I tests the safety, side effects, and best dose of E6201 in combination with dabrafenib in treating patients with BRAF V600 mutated melanoma that has spread to the central nervous system (central nervous system metastases). E6201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Dabrafenib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving E6201 and dabrafenib together may work better in treating patients with BRAF V600 mutated melanoma that has spread to the central nervous system than either drug alone.
Recruiting1 award Phase 130 criteria
More about Mahesh Seetharam
Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Mahesh Seetharam has experience with
- Doxorubicin
- Dabrafenib
- TSR-022
- Lurbinectedin
- Pembrolizumab
- Sonidegib
Breakdown of trials Mahesh Seetharam has run
Tumors
Cancer
Solid Tumors
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mahesh Seetharam specialize in?
Mahesh Seetharam focuses on Tumors and Cancer. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are BRAF positive.
Is Mahesh Seetharam currently recruiting for clinical trials?
Yes, Mahesh Seetharam is currently recruiting for 11 clinical trials in Scottsdale Arizona. If you're interested in participating, you should apply.
Are there any treatments that Mahesh Seetharam has studied deeply?
Yes, Mahesh Seetharam has studied treatments such as Doxorubicin, Dabrafenib, TSR-022.
What is the best way to schedule an appointment with Mahesh Seetharam?
Apply for one of the trials that Mahesh Seetharam is conducting.
What is the office address of Mahesh Seetharam?
The office of Mahesh Seetharam is located at: Mayo Clinic, Scottsdale, Arizona 85259 United States. This is the address for their practice at the Mayo Clinic.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.